Patents by Inventor Upasana Ray

Upasana Ray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9931393
    Abstract: Methods of eliciting an immune response to a JC polyomavirus (JCV) by administering an effective amount of an immunogenic composition including an isolated JCV VP1 polypeptide or a nucleic acid encoding the VP1 polypeptide to a subject are provided. VP1 polypeptides and immunogenic compositions suitable for use in the methods are provided, including JCV genotype 2 VP1 polypeptides and/or JCV genotype 3 polypeptides. Methods of identifying a subject at risk of developing progressive multifocal leukoencephalopathy (PML) are also provided. In some embodiments, the methods include obtaining a biological sample from a subject, detecting presence or absence of JCV neutralizing antibodies in the sample from the subject, and identifying that the subject is at risk of developing PML if there is an absence of detectable JCV neutralizing antibodies in the sample from the subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 3, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christopher B. Buck, Upasana Ray, Diana V. Pastrana
  • Publication number: 20160317643
    Abstract: Disclosed herein are methods of eliciting an immune response to a JC polyomavirus (JCV) by administering an effective amount of an immunogenic composition including an isolated JCV VP1 polypeptide or a nucleic acid encoding the VP1 polypeptide to a subject. VP1 polypeptides and immunogenic compositions suitable for use in the methods are disclosed herein, including JCV genotype 2 VP1 polypeptides and/or JCV genotype 3 polypeptides. Also disclosed are methods of identifying a subject at risk of developing progressive multifocal leukoencephalopathy (PML). In some embodiments, the methods include obtaining a biological sample from a subject, detecting presence or absence of JCV neutralizing antibodies in the sample from the subject, and identifying that the subject is at risk of developing PML if there is an absence of detectable JCV neutralizing antibodies in the sample from the subject.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Applicant: The United States of America, as represented by The Secretary, Dept. of Health and Human Services
    Inventors: Christopher B. BUCK, Upasana RAY, Diana V. PASTRANA
  • Publication number: 20090233868
    Abstract: Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and in vivo and can compete against cellular La protein in binding to the HCV RNA. It is also shown here that this 7-mer peptide is able to inhibit HCV-IRES mediated translation in vivo which, in turn, leads to decreased viral replication.
    Type: Application
    Filed: September 24, 2008
    Publication date: September 17, 2009
    Inventors: Saumitra Das, Siddhartha Roy, Upasana Ray, Asit Kumar Manna, Tanmoy Mondal, Romi Gupta, Renuka Pudi, Sudhamani Sonny